The CAO and General Counsel of Pacira Pharmaceuticals (PCRX) is Selling Shares


Yesterday, the CAO and General Counsel of Pacira Pharmaceuticals (NASDAQ: PCRX), Kristen Marie Williams, sold shares of PCRX for $67.36K.

In addition to Kristen Marie Williams, 4 other PCRX executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $74.61 million and GAAP net loss of $10.68 million. In comparison, last year the company earned revenue of $69.28 million and had a GAAP net loss of $19.87 million. Currently, Pacira Pharmaceuticals has an average volume of 1.05M.

Based on 10 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $46.44, reflecting a -19.3% downside. Three different firms, including BMO Capital and Merrill Lynch, currently also have a Sell rating on the stock.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts